PRIS, CMED, PARD, - CRWESelect.com Stock News! Promotora De Informaciones SA, China Medical Technologies, Poniard Pharmaceuticals (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) November 18, 2011 -- To view video, and read the full article visit URL http://crweselect.com/27399/stock-alerts/pris-cmed-pard-crweselectcom-stock-news-promotora-de-informaciones-sa-china-medical-technologies-poniard-pharmaceuticals-video-included-inside/

Promotora De Informaciones SA (NYSE:PRIS)

According to reports, Inmobiliaria Carso SA de CV, a company owned by Mexican billionaire Carlos Slim, has acquired a 3.2% stake in Spain's media group Promotora de Informaciones SA - symbol PRIS

PRIS, together with its subsidiaries, operates as a multimedia company in Spain and internationally. The company operates in four segments: Audiovisual, Education, Radio, and Press.

For more information about PRIS please visit http://www.prisa.es

****

China Medical Technologies, Inc. (NASDAQ:CMED)

CMED, announced its unaudited financial results for the second fiscal quarter ended September 30, 2011 ("2Q FY2011") today. CMED posting revenues of $37.4 million dollars, an 18.1% increase year over year.

CMED is a leading China -based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors.

For more information about CMED please visit http://www.chinameditech.com

****

Poniard Pharmaceuticals, Inc. (NASDAQ:PARD)

PARD announced today that it has entered into a licensing agreement with an undisclosed party for rights to Poniard's focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK. Under terms of the agreement, Poniard granted the licensee worldwide rights for the development and commercialization of any FAK-related products, including the preclinical candidate, in exchange for an upfront cash payment of $250,000, milestone payments and other considerations, as well as royalty payments on net sales of any products covered by the license. The licensee is responsible for all costs related to further development and commercialization.

PARD is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. Poniard's lead product candidate is picoplatin, a new generation platinum-based cancer therapy designed to treat solid tumors that are resistant to existing platinum-based therapies. Assuming receipt of shareholder approvals and satisfaction of other conditions to closing, the merger of Poniard and ALLOZYNE, Inc. will result in a Nasdaq-listed specialty pharmaceutical company focused on developing and commercializing therapeutics in the areas of autoimmune and inflammatory disease and cancer. The combined company is expected to seek a partnership for the continued development of picoplatin.

For more information about PARD please visit http://www.poniard.com/

To read the full article visit URL http://crweselect.com/27399/stock-alerts/pris-cmed-pard-crweselectcom-stock-news-promotora-de-informaciones-sa-china-medical-technologies-poniard-pharmaceuticals-video-included-inside/

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

PRIScrweselect1118
CMEDcrweselect1118
PARDcrweselect1118

Carlos Slim     china medical technologies     CMED     PARD     Poniard Pharmaceuticals     PRIS     Promotora De Informaciones SA     select